December 14, 2023 | Issue #80

Hello! We recently launched something new on our website. Have you seen it yet?

In this week's newsletter:💉 IV Therapy for Longevity 💰 Fountain Life Grows🌐 Sniff Bad Stuff?    

Longevity Elixir or Hype? Investigating the Impact of IV Therapy on Aging

If you live in or near a major metropolitan area, you’ve probably seen the rise of intravenous (IV) therapy. Packing a punch in a small bag of nutrients, IV drip therapy, or “IV drips,” can be found in IV clinics, IV bars, mobile IV therapy, IV lounges, and general health and wellness centered clinics. IV fluids used to be something you’d only receive when you were sick in the hospital. Today it has become known as a way to boost your health in a short period of time, even if you’re healthy. In fact, IV hydration therapy is purported to help with hangovers, your immune system, low energy, dehydration, food poisoning, and the ability get your body back to tiptop shape. In a day and age of fast food, quick information, and instant gratification, the promise of a quick fix for our health sounds enticing. Does the reality match the hype? Let’s explore if IV therapy is as beneficial to your health and longevity as the marketing claims...

• The National Institute on Aging is hiring a Senior Program Manager APPLY HERE.

• Browse thousands of jobs in the longevity industry, updated daily, in Spannr's new Jobs database HERE. 

• Fountain Life, an advanced diagnostics and preventative health company, announced the acquisition of LifeOmic, a health data technology company powering precision health. Through the transaction, Fountain Life will own all of LifeOmic’s intellectual property, including the LifeOmic Platform and software, LifeOmic Patient Mobile App, and a suite of consumer-focused mobile apps and science-backed educational content. In addition, Fountain Life will add a worldclass team of coders, designers and engineers whose expertise in data platforms, AI-systems and medical technology development and deployment will help to expand Fountain Life’s data-driven preventative care membership services. Financial terms of the transaction were not disclosed.

• Explore Spannr's Longevity Investor database HERE.

• FDA Approves World’s First Crispr Gene-Editing Drug for Sickle-Cell Disease (WSJ)

• The Scent of Longevity: How Smelling Harmful Substances May Prolong Life (SciTechDaily)

• Living machine? Scientists create biocomputer combining circuits with real human brain tissue (Study Finds)

• People with children live longer, study finds — but only this many kids (NY Post)

• Longevity Cities Can Improve Human And Planetary Health And Drive Economic Growth (Forbes)

• Chinese scientists develop powerful hydrogen therapy that could reverse ageing (SCMP)

Performance:

Latest Price: $98.757d-Return: 7.8%Market Cap: $10.1b

Big Movers:Brainstorm (BCLI): -30%Cognition (CGTX): 29.41%Capricor (CAPR): 24.55%

ABOUT SPANNR

We are dedicated to helping people understand the biggest business and health story of all time: the unprecedented transformation of society that will result from extending human healthspan and lifespan.

If you have any questions about Spannr or want to get to know us better, 

contact us

 – we'd love to hear from you. We appreciate your interest in what we are creating.